benefits of microdosing glp-1 Agonists: Using Semaglutide, Tirzepatide, and Orforglipron for Weight Loss and Obesity People Are Microdosing Weight-Loss Drugs
Description
Optimal results often build over 36 months or more
And it might be the most important one in this entire guide
Drug interactions: Orforglipron's CYP3A-mediated metabolism raises the potential for drug-drug interactions with strong CYP3A inhibitors and inducers
& Jenkins, A
8-13 For a detailed discussion of cardiovascular outcome trials (CVOTs) completed with agents from the GLP-1 RA class, please refer to the companion lesson titled: What do we Currently Know about the Cardiovascular Benefits of GLP-1 RAs
Published March 26, 2024
